Regentis Develops Solvent-Free GelrinC Process Boost
HERZLIYA, Israel, March 17, 2026 Regentis Biomaterials Ltd. has announced a breakthrough solvent-free manufacturing process for its lead regenerative...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
HERZLIYA, Israel, March 17, 2026 Regentis Biomaterials Ltd. has announced a breakthrough solvent-free manufacturing process for its lead regenerative...
HERZLIYA, ISRAEL — December 5, 2025 — Regentis Biomaterials Ltd., a regenerative medicine MedTech company developing innovative tissue-repair solutions,...
